NASDAQ:RLYP (RLYP) (RLYP) Stock Price, News & Analysis → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free RLYP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$31.99▼$31.9950-Day Range N/A52-Week Range$10.26▼$32.12VolumeN/AAverage Volume2.93 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (RLYP) alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About (RLYP) Stock (NASDAQ:RLYP)Relypsa, Inc. is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company's technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address. Its polymers are non-absorbed, meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body. Its polymer technology may be able to address many health conditions in need of viable treatment options. Its VELTASSA (patiromer) for oral suspension is a commercialized medicine resulting from its polymer technology platform. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. Available in powder form, VELTASSA is mixed with water and taken daily. VELTASSA's spherical beads bind to potassium in exchange for calcium, primarily in the colon.Read More Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one RLYP Stock News HeadlinesJanuary 13, 2024 | morningstar.comLudwig Enterprises Inc LUDGOctober 25, 2023 | investing.comRLYP Historical DataMarch 29, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…April 6, 2023 | nasdaq.comTECK October 20th Options Begin TradingApril 5, 2023 | thestreet.comRelypsa Expects Approval Decision Wednesday on Potassium-Lowering DrugApril 4, 2023 | msn.comTwo-wheeler sales plunge to 7-year low in FY23; tractor sales languish as inflation bites rural India hardApril 4, 2023 | msn.comSeason Preview: Defending State Champion Summit High School Girls Lacrosse Team Ready to 'Make It Count'October 28, 2022 | msn.comBruins send Jack Studnicka to Vancouver in a trade that clears roster room, brings back prospectsMarch 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…October 27, 2022 | msn.comBrad Marchand makes his season debut for the Bruins against the Red WingsOctober 27, 2022 | msn.comBrad Marchand will make his season debut for Bruins on Thursday vs. Red WingsSeptember 14, 2022 | thestreet.comRelypsa Fielding Takeout Offers, Shares Move HigherAugust 20, 2022 | msn.comKagiso Rabada becomes 7th South African bowler to take 250 Test wickets; joins Ashwin, Steyn in elite listAugust 19, 2022 | msn.com‘Chaotic’ incident on GCT school bus under investigationMay 3, 2022 | thestreet.comJim Cramer's 'Mad Money' Recap: More Items Off Cramer's ChecklistMarch 5, 2022 | thestreet.comJim Cramer's Top Stock Picks: GD PTCT RLYP HON PEPSee More Headlines Receive RLYP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (RLYP) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:RLYP CUSIPN/A CIK1416792 Webwww.relypsa.com Phone+1-650-4219500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report RLYP Stock Analysis - Frequently Asked Questions What other stocks do shareholders of (RLYP) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (RLYP) investors own include Royalty Pharma (RPRX), Synergy Pharmaceuticals (SGYP), Akorn (AKRX), Novavax (NVAX), Verastem (VSTM), Skechers U.S.A. (SKX), Sarepta Therapeutics (SRPT), Integrated Device Technology (IDTI) and Gilead Sciences (GILD). This page (NASDAQ:RLYP) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (RLYP) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.